Published in Eur J Gastroenterol Hepatol on April 01, 2009
Atrial fibrillation in patients with gastroesophageal reflux disease: a comprehensive review. World J Gastroenterol (2014) 1.21
Technical problems produced by the Bravo pH test in nonerosive reflux disease patients. World J Gastroenterol (2010) 1.06
Interobserver reproducibility in pathologist interpretation of columnar-lined esophagus. Virchows Arch (2015) 0.75
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med (2007) 5.62
Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA (2011) 4.74
Liver enzyme alteration: a guide for clinicians. CMAJ (2005) 3.42
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30
Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med (2007) 3.26
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol (2009) 3.18
Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med (2009) 3.12
Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals. Am J Gastroenterol (2007) 2.89
Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials. Am J Gastroenterol (2009) 2.84
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol (2006) 2.64
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst (2012) 2.49
Guidelines for the management of dyspepsia. Am J Gastroenterol (2005) 2.39
The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol (2008) 2.36
Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol (2003) 2.34
Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol (2008) 2.32
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology (2007) 2.32
Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med (2008) 2.22
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
An inter- and intra-laboratory comparison of breath ¹³CO₂analysis. Aliment Pharmacol Ther (2003) 2.03
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci (2013) 2.00
Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology (2007) 1.98
A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol (2009) 1.89
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ (2013) 1.74
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Timing of precut procedure does not influence success rate and complications of ERCP procedure: a prospective randomized comparative study. Gastrointest Endosc (2009) 1.69
Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine (2004) 1.65
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol (2013) 1.65
Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol (2006) 1.64
The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol (2008) 1.64
Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis (2004) 1.63
Connections between genetics and clinical data: Role of MCP-1, CFTR, and SPINK-1 in the setting of acute, acute recurrent, and chronic pancreatitis. Am J Gastroenterol (2009) 1.63
Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol (2008) 1.59
Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin Gastroenterol Hepatol (2010) 1.58
Dyspeptic symptoms and endoscopic findings in the community: the Loiano-Monghidoro study. Am J Gastroenterol (2009) 1.58
Treatment of Helicobacter pylori infection. BMJ (2008) 1.56
Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol (2012) 1.54
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int (2012) 1.53
Can the clinical history distinguish between organic and functional dyspepsia? JAMA (2006) 1.51
Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg (2012) 1.50
Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. Eur J Gastroenterol Hepatol (2012) 1.47
Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut (2010) 1.44
Identification of a lower grade muconodular subtype of gastric mucinous cancer. Virchows Arch (2004) 1.43
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol (2006) 1.43
Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Intern Emerg Med (2011) 1.42
Investigating dyspepsia. BMJ (2008) 1.41
Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med (2010) 1.40
Obesity does not affect treatment outcomes with proton pump inhibitors. J Clin Gastroenterol (2013) 1.40
Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J Emerg Surg (2010) 1.39
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis (2011) 1.37
Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol (2005) 1.33
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol (2009) 1.32
Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol (2011) 1.29
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol (2012) 1.28
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol (2008) 1.27
Epidemiology of Helicobacter pylori infection. Helicobacter (2014) 1.26
Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res (2003) 1.25
The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med (2002) 1.25
Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab (2003) 1.22
Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res (2003) 1.20
NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol (2013) 1.20
Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol (2012) 1.18
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation (2003) 1.16
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. Acta Biomed (2007) 1.13
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J (2013) 1.12
How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol (2012) 1.11
Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease--an IG-IBD study. Am J Gastroenterol (2005) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11
Diverticular disease in the elderly. Dig Dis (2007) 1.11
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res (2008) 1.09
Non-erosive reflux disease is more complex than negative endoscopy only. Am J Gastroenterol (2013) 1.09
Comment to "predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease". Dig Liver Dis (2013) 1.07
Which anticoagulant drug should be used to treat portal vein thrombosis in patients with chronic liver disease? Clin Gastroenterol Hepatol (2012) 1.07
Esophageal acid exposure still plays a major role in patients with NERD. J Gastroenterol (2013) 1.06
Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology (2010) 1.06
Non-erosive reflux disease patients are more complex than the sole endoscopy tells us. Clin Oral Investig (2013) 1.06
Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol (2013) 1.05
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies. Clin Cancer Res (2005) 1.04
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. J Gastroenterol (2014) 1.04
Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia. Hum Pathol (2006) 1.03
Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol (2002) 1.03
External validation of the platelet count/spleen diameter ratio for the diagnosis of esophageal varices in hepatitis C virus-related cirrhosis. Dig Dis Sci (2008) 1.02
Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem Cell Biol (2015) 1.02
Gastritis: the histology report. Dig Liver Dis (2011) 1.02
Diagnosis and management of gastric antral vascular ectasia. World J Gastrointest Endosc (2013) 1.01
A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol (2004) 1.01